DENVER, Aug. 28, 2026 (GLOBE NEWSWIRE) -- For NeOnc Technologies Holdings (NASDAQ: NTHI), the most important part of the NEO100 story may no longer be whether the company can produce a meaningful signal in recurrent brain cancer. After its latest Phase 2a readout, the bigger move is whether those results can support a credible path toward registration.
Read more at globenewswire.comNeOnc’s Phase 2A Success Could Set the Stage for Something Much Bigger
Barchart·08/28/2026 09:07:00
语音播报
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.